Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) presenting with classic or generalized lichenoid and inflammatory phenotypes vs other non-classic phenotypes and with Eczema Area and Severity Index (EASI) scores < 29 vs ≥ 29 showed an early response to dupilumab by achieving a mild disease state.
Major finding: Factors with a significant predictive value for an early response to dupilumab included the classic phenotype (odds ratio [OR] 6.92; 95% CI 2.04-23.48) or generalized lichenoid and inflammatory phenotypes (OR 4.22; 95% CI 1.22-14.66) vs the nummular eczema phenotype and a baseline EASI score of ≤ 24 (OR 3.13; 95% CI 1.81-5.41) or 24-29 (OR 1.79; 95% CI 1.05-3.07) vs ≥ 29.
Study details: Findings are from a retrospective single-center observational study including 492 patients (age > 12 years) with moderate-to-severe AD treated with dupilumab.
Disclosures: This study did not receive any external funding. S Ferrucci and AV Marzano declared serving as speakers or advisory board members of various organizations. The other authors declared no conflicts of interest.
Source: Ferrucci S et al. Predictive factors of early response to dupilumab in patients with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12(20):6575 (Oct 17). doi: 10.3390/jcm12206575.